Skip to main content

E2F-1 Antibody (23GB1505)

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-51402

Catalog #
Availability
Size / Price
Qty
Loading...
NBP3-51402-100ul
NBP3-51402-20ul

Key Product Details

Species Reactivity

Human, Mouse, Rat

Applications

Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Knockdown Validated

Label

Unconjugated

Antibody Source

Monoclonal Rabbit IgG Clone # 23GB1505

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

A synthesized peptide derived from human E2F-1 (Uniprot: Q01094)

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for E2F-1 Antibody (23GB1505)

E2F-1 Antibody (23GB1505)

Immunocytochemistry/ Immunofluorescence: E2F-1 Antibody (23GB1505)[NBP3-51402] -

Immunocytochemical staining of C2C12 cells with E2F-1 antibody (1:1,000). Nuclei were stained blue with DAPI; E2F-1 was stained magenta with Alexa Fluor(R) 647. Images were taken using Leica stellaris 5. Protein abundance based on laser Intensity and smart gain: High. Scale bar, 20 um.
E2F-1 Antibody (23GB1505)

Flow Cytometry: E2F-1 Antibody (23GB1505)[NBP3-51402] -

Flow cytometric analysis of E2F-1expression in C2C12 cells using E2F-1 antibody (1:2,000). Green, isotype control; red, E2F transcription factor 1.
E2F-1 Antibody (23GB1505)

Flow Cytometry: E2F-1 Antibody (23GB1505)[NBP3-51402] -

Validation of E2F-1 knockdown using flow cytometry. Wild-type(WT, Blue) and knockdown(KD, Green) HeLa cells were stained with E2F-1 antibody (1:2,000) and analyzed using BD flow cytometer.

Applications for E2F-1 Antibody (23GB1505)

Application
Recommended Usage

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Immunocytochemistry/ Immunofluorescence

Optimal dilutions of this antibody should be experimentally determined.

Knockdown Validated

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Affinity purified

Formulation

PBS (pH 7.4), 50% glycerol

Preservative

0.02% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C. Avoid freeze-thaw cycles.

Background: E2F-1

E2F1 is encoded by this gene is a member of the E2F family of transcription factors. The E2F family plays a crucial role in the control of cell cycle and action of tumor suppressor proteins and is also a target of the transforming proteins of small DNA tumor viruses. The E2F proteins contain several evolutionally conserved domains found in most members of the family. These domains include a DNA binding domain, a dimerization domain which determines interaction with the differentiation regulated transcription factor proteins (DP), a transactivation domain enriched in acidic amino acids, and a tumor suppressor protein association domain which is embedded within the transactivation domain. This protein and another 2 members, E2F2 and E2F3, have an additional cyclin binding domain. This protein binds preferentially to retinoblastoma protein pRB in a cell-cycle dependent manner. It can mediate both cell proliferation and p53-dependent/independent apoptosis.

Long Name

E2F Transcription Factor 1

Alternate Names

E2F1, PBR3, RBAP-1, RBBP-3, RBP3

Gene Symbol

E2F1

Additional E2F-1 Products

Product Documents for E2F-1 Antibody (23GB1505)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Product Specific Notices for E2F-1 Antibody (23GB1505)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...